Emil D. Kakkis, M.D., Ph.D.

Emil D. Kakkis, M.D., Ph.D.

President and Chief Executive OfficeratUltragenyx Pharmaceutical· In proxies 2021–2025

Pay in FY2025-17% from the year before · Ultragenyx Pharmaceutical stock -45.3% the same year

Emil D. Kakkis, M.D., Ph.D. was paid $11.4M in FY2025 (Dec), down 17%. Ultragenyx Pharmaceutical stock fell 45.3% that year.

Pay$100 in the stock at the end of FY20 → $17
Pay is from the Summary Compensation Table of each Ultragenyx Pharmaceutical proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Ultragenyx PharmaceuticalPublic company · 5 yr
    • President and Chief Executive Officer2021 – Present · 5 yrStock in role -90%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?